SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).
Epistemonikos ID: 326a58d65c4047842b8c27ff82723061def84a9d
First added on: Feb 19, 2024